NEWS
Our Latest News
ARCHIMED acquires cell line development pioneer ExcellGene to accelerate expansion into biosimilars and high-performance transfection solutions
Global private equity healthcare specialist ARCHIMED acquires a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics.
ARCHIMED appoints three new operating and strategic partners
November
19,
2019
Flash News – Bomi Group launches its 2019-2020 Welfare Plan
November
19,
2019
Provepharm Life Solutions lauréate du prix Galien MedStartUp 2018
November
19,
2019
ARCHIMED delivers three times its investment and a 36 percent internal rate of return with the sale of Italian dental services chain, Primo Group
October
15,
2019
ARCHIMED expands neurodiagnostic business in Europe and the US
September
23,
2019
368